Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA CACS15 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 25/February/2019, 12.51 am